Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Go or no go? Roche’s fresh start for a new year
EP Vantage
Mon, 12/20/21 - 10:59 am
Tags:
FDA, Roche, Novartis, Pfizer, AstraZeneca, Cibinqo, Lynparza, Tezspire, Vyvgart, faricimab
Novartis Deepens BeiGene Oncology Pact, Posts Disappointing Results in CSU
BioSpace
Mon, 12/20/21 - 10:49 am
Tags:
Novartis, BeiGene, China, ociperlimab, anti-TIGIT
Mesoblast considers plans for COVID treatment after Novartis exits deal
Biopharma Reporter
Mon, 12/20/21 - 10:48 am
Tags:
Mesoblast, Novartis, clinical trials, COVID-19
Mesoblast pummelled as Novartis exits COVID deal
Pharmaforum
Tue, 12/14/21 - 10:42 am
Tags:
Novartis, Mesoblast, stem cells, remestemcel-L, COVID-19
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
Tags:
licensing, GSK, Alector, Novartis, BeiGene, Pfizer, Arvinas, iTeos Therapeutics, Bristol Myers Squibb, Eisai
Novartis works on pan-coronavirus pill, eyes 2022 human testing
Fierce Biotech
Thu, 12/9/21 - 11:01 am
Tags:
Novartis, pan-coronavirus pill, COVID-19, drug development
Novartis petitions FDA to block 18 generic competitors for its megablockbuster heart drug until 2024
Endpoints
Mon, 12/6/21 - 10:52 am
Tags:
Novartis, generics, Entresto
A startup led by Novartis veteran raises $80M to develop gene therapies for the brain
BioPharma Dive
Thu, 12/2/21 - 12:15 pm
Tags:
AviadoBio, gene therapy, Novartis, Lisa Deschamps, neurodegenerative disease
UCB Signs Up To $1.5 Bln Deal With Novartis To Co-develop Two Parkinson's Disease Drugs
NASDAQ
Thu, 12/2/21 - 10:39 am
Tags:
Novartis, UCB Pharma, drug development, Parkinson's Disease
Get ready for M&A: Large biopharma companies will have $1.7T in dealmaking firepower next year, analyst says
Fierce Pharma
Wed, 12/1/21 - 11:28 am
Tags:
M&A, pharma industry, Big Pharma, JNJ, Pfizer, Moderna Therapeutics, Novartis, BioNTech, GSK
Spinoff updates: Merck’s Organon and Novartis’ Sandoz
Generics and Biosimilar Initiative
Mon, 11/29/21 - 11:08 pm
Tags:
spinoffs, Merck, Organon, earnings, Novartis, Sandoz, biosimilars
Novartis plans unconventional sales strategy for new heart drug
Beckers Hospital Review
Mon, 11/22/21 - 10:29 pm
Tags:
Novartis, pharma marketing, EHRs, Leqvio
EQT, Biontech investor family consider Sandoz bid
Yahoo/Reuters
Fri, 11/19/21 - 11:12 am
Tags:
EQT, BioNTech, Sandoz, generics, Novartis, M&A
Where will Novartis spend the $21B from Roche stake sale? Alnylam buyout could be one: report
Fierce Pharma
Thu, 11/18/21 - 10:50 am
Tags:
Novartis, Roche, M&A, Alnylam
Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds
MedCity News
Tue, 11/16/21 - 10:31 am
Tags:
Acelyrin, Affibody, antibodies, monoclonal antibodies, immunology, Novartis, Eli Lilly
The quest for efficacy in pancreatic cancer
EP Vantage
Thu, 11/11/21 - 10:53 am
Tags:
pancreatic cancer, Novartis, FibroGen, Tyme Technologies, Erytech, Rafeal Pharmaceuticals
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Fierce Biotech
Tue, 11/9/21 - 10:40 am
Tags:
Novartis, Xencor, bispecifics, blood cancers
Mixed court decisions for Novartis in DC and Sanofi, Novo Nordisk in NJ further complicate whose interpretation of 340B is correct
Endpoints
Mon, 11/8/21 - 10:46 am
Tags:
legal, drug discounts, 340B, Medicare, Sanofi, Novartis, Novo Nordisk
Swiss socialists say government should buy Sandoz
Pharmaforum
Mon, 11/8/21 - 10:38 am
Tags:
Switzerland, Novartis, Sandoz, M&A, generics
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Pharmaforum
Fri, 11/5/21 - 09:54 am
Tags:
Novartis, iptacopan, C3G, kidney disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.